228 related articles for article (PubMed ID: 21875873)
1. Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria.
Iking-Konert C; Aringer M; Wollenhaupt J; Mosch T; Tuerk S; Feist E; Burmester GR
Ann Rheum Dis; 2011 Nov; 70(11):1986-90. PubMed ID: 21875873
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA).
Burmester GR; Feist E; Kellner H; Braun J; Iking-Konert C; Rubbert-Roth A
Ann Rheum Dis; 2011 May; 70(5):755-9. PubMed ID: 21187298
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants.
Smolen JS; Aletaha D
Arthritis Rheum; 2011 Jan; 63(1):43-52. PubMed ID: 21204103
[TBL] [Abstract][Full Text] [Related]
4. Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice.
Backhaus M; Kaufmann J; Richter C; Wassenberg S; Roske AE; Hellmann P; Gaubitz M
Clin Rheumatol; 2015 Apr; 34(4):673-81. PubMed ID: 25630309
[TBL] [Abstract][Full Text] [Related]
5. Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: results from 3 years of prospectively registered data.
Nakashima Y; Kondo M; Fukuda T; Harada H; Horiuchi T; Ishinishi T; Jojima H; Kuroda K; Miyahara H; Maekawa M; Nishizaka H; Nagamine R; Nakashima H; Otsuka T; Shono E; Suematsu E; Shimauchi T; Tsuru T; Wada K; Yoshizawa S; Yoshizawa S; Iwamoto Y
Mod Rheumatol; 2014 Mar; 24(2):258-64. PubMed ID: 24593201
[TBL] [Abstract][Full Text] [Related]
6. Active foot synovitis in patients with rheumatoid arthritis: applying clinical criteria for disease activity and remission may result in underestimation of foot joint involvement.
Wechalekar MD; Lester S; Proudman SM; Cleland LG; Whittle SL; Rischmueller M; Hill CL
Arthritis Rheum; 2012 May; 64(5):1316-22. PubMed ID: 22135142
[TBL] [Abstract][Full Text] [Related]
7. Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study.
Lee YC; Cui J; Lu B; Frits ML; Iannaccone CK; Shadick NA; Weinblatt ME; Solomon DH
Arthritis Res Ther; 2011 Jun; 13(3):R83. PubMed ID: 21651807
[TBL] [Abstract][Full Text] [Related]
8. High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis.
Daïen CI; Gailhac S; Audo R; Mura T; Hahne M; Combe B; Morel J
Rheumatology (Oxford); 2015 Apr; 54(4):601-8. PubMed ID: 25231180
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of tocilizumab in Korean patients with active rheumatoid arthritis.
Baek HJ; Lim MJ; Park W; Park SH; Shim SC; Yoo DH; Kim HA; Lee SK; Lee YJ; Park YE; Cha HS; Song YW
Korean J Intern Med; 2019 Jul; 34(4):917-931. PubMed ID: 29334721
[TBL] [Abstract][Full Text] [Related]
10. The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis.
Tanaka Y; Smolen JS; Jones H; Szumski A; Marshall L; Emery P
Arthritis Res Ther; 2019 Jul; 21(1):164. PubMed ID: 31277720
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of ACR/EULAR remission criterion of rheumatoid arthritis published in 2011 year with the other common remission criteria].
Lu XY; Li C; Zhao JX; Li ZG
Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 45(2):260-3. PubMed ID: 23591348
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice.
Bykerk VP; Östör AJK; Alvaro-Gracia J; Pavelka K; Román Ivorra JA; Nurmohamed MT; Luder Y; Sidiropoulos PNM; Devenport J; Sibilia J
Clin Rheumatol; 2019 Sep; 38(9):2411-2421. PubMed ID: 31028551
[TBL] [Abstract][Full Text] [Related]
13. Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice.
Bykerk VP; Ostör AJ; Alvaro-Gracia J; Pavelka K; Ivorra JA; Graninger W; Bensen W; Nurmohamed MT; Krause A; Bernasconi C; Stancati A; Sibilia J
Ann Rheum Dis; 2012 Dec; 71(12):1950-4. PubMed ID: 22615456
[TBL] [Abstract][Full Text] [Related]
14. Two-year efficacy of tocilizumab in patients with active rheumatoid arthritis in clinical practice.
Notario Ferreira I; Ferrer González MA; Morales Garrido P; González Utrilla A; García Sanchez A; Soto Pino MJ; Suero Rosario E; Caro Hernández C; Añón Oñate I; Pérez Albaladejo L; Cáliz Cáliz R
Reumatol Clin; 2017; 13(2):78-84. PubMed ID: 27174398
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial.
van der Leeuw MS; Welsing PMJ; de Hair MJH; Jacobs JWG; Marijnissen ACA; Linn-Rasker SP; Fodili F; Bos R; Tekstra J; van Laar JM
Trials; 2020 Apr; 21(1):313. PubMed ID: 32248829
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
Genovese MC; McKay JD; Nasonov EL; Mysler EF; da Silva NA; Alecock E; Woodworth T; Gomez-Reino JJ
Arthritis Rheum; 2008 Oct; 58(10):2968-80. PubMed ID: 18821691
[TBL] [Abstract][Full Text] [Related]
17. The prevalence of clinical remission in RA patients treated with anti-TNF: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
de Punder YM; Fransen J; Kievit W; Houtman PM; Visser H; van de Laar MA; van Riel PL
Rheumatology (Oxford); 2012 Sep; 51(9):1610-7. PubMed ID: 22539487
[TBL] [Abstract][Full Text] [Related]
18. Remission in rheumatoid arthritis: wishful thinking or clinical reality?
Sesin CA; Bingham CO
Semin Arthritis Rheum; 2005 Dec; 35(3):185-96. PubMed ID: 16325659
[TBL] [Abstract][Full Text] [Related]
19. Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice.
Pers YM; Fortunet C; Constant E; Lambert J; Godfrin-Valnet M; De Jong A; Mercier G; Pallot Prades B; Wendling D; Gaudin P; Jorgensen C; Marotte H; Maillefert JF
Rheumatology (Oxford); 2014 Jan; 53(1):76-84. PubMed ID: 24056521
[TBL] [Abstract][Full Text] [Related]
20. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register.
Kristensen LE; Kapetanovic MC; Gülfe A; Söderlin M; Saxne T; Geborek P
Rheumatology (Oxford); 2008 Apr; 47(4):495-9. PubMed ID: 18316338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
